A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine.

Manzano, J. L.; Rivera, F.; Galan, MaCarmen; Valladares, Manuel; Pericay, C.; Méndez, María José; Safont, María José; Irigoyen, A.; Arriví, A.; Sastre, J.

doi:10.1200/jco.2010.28.15_suppl.4094

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Erlotinib combined with gemcitabine improved overall survival significantly for patients younger than 65 years old compared with a group treated with gemcitabine only as reported in a phase III trial recently [105]. Patients with skin rashes during treatment with erlotinib had better overall survival than the patients with fewer or no rashes [103, 104]. Combination of erlotinib (100 mg/day) with gemcitabine (1,000 mg/m 2 ) did not show any benefit in overall survival rate compared with gemcitabine (1,000 mg/m 2 ) combined with docetaxel (35 mg/m 2 ) in a phase II study from 69 metastatic pancreatic cancer patients [106].…”

Section: Introductionmentioning

confidence: 99%

Molecular Targeted Approaches for Treatment of Pancreatic Cancer

Huang¹,

Saluja²,

Dudeja³

et al. 2011

CPD

View full text Add to dashboard Cite

Human pancreatic cancer remains a highly malignant disease with almost similar incidence and mortality despite extensive research. Many targeted therapies are under development. However, clinical investigation showed that single targeted therapies and most combined therapies were not able to improve the prognosis of this disease, even though some of these therapies had excellent anti-tumor effects in pre-clinical models. Cross-talk between cell proliferation signaling pathways may be an important phenomenon in pancreatic cancer, which may result in cancer cell survival even though some pathways are blocked by targeted therapy. Pancreatic cancer may possess different characteristics and targets in different stages of pathogenesis, maintenance and metastasis. Sensitivity to therapy may also vary for cancer cells at different stages. The unique pancreatic cancer structure with abundant stroma creates a tumor microenvironment with hypoxia and low blood perfusion rate, which prevents drug delivery to cancer cells. In this review, the most commonly investigated targeted therapies in pancreatic cancer treatment are discussed. However, how to combine these targeted therapies and/or combine them with chemotherapy to improve the survival rate of pancreatic cancer is still a challenge. Genomic and proteomic studies using pancreatic cancer samples obtained from either biopsy or surgery are recommended to individualize tumor characters and to perform drug sensitivity study in order to design a tailored therapy with minimal side effects. These studies may help to further investigate tumor pathogenesis, maintenance and metastasis to create cellular expression profiles at different stages. Integration of the information obtained needs to be performed from multiple levels and dimensions in order to develop a successful targeted therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular Targeted Approaches for Treatment of Pancreatic Cancer

Huang¹,

Saluja²,

Dudeja³

et al. 2011

CPD

View full text Add to dashboard Cite

show abstract

“…Another predictive factor in erlotinib-containing treatment regimens is the occurrence of a rash. In several phase III trials comparing erlotinib in combination with gemcitabine with gemcitabine alone in patients with unresectable advanced disease (AVITA, PA.3, AIO PK and PANTAR), occurrence of a treatment-related rash was indicative of response to erlotinib and resulted in significantly (p < 0.001 for AVITA, PA.3 and AIO PK; p = 0.001 for PANTAR) improved survival, compared with those patients who did not develop a rash [81][82][83][84].…”

Section: Prognostic and Predictive Factors In Pancreatic Cancermentioning

confidence: 99%

Recent Developments and Current Issues in the Treatment of Pancreatic Cancer

Oettle¹

2013

JCT

View full text Add to dashboard Cite

Presently, many questions exist about what the optimal regimen comprises for all stages and treatment settings for pancreatic cancer. Since the CONKO-001 trial, adjuvant therapy following resection has become standard of care; however, outcomes are poor, with most patients experiencing disease recurrence, and new therapies have yet to be validated. Furthermore, the value of adjuvant radiotherapy has still not been clearly defined. Targeted treatment in combination with chemotherapy has been mostly disappointing so far in the adjuvant setting but immunotherapy holds potential for improving survival outcomes. Neoadjuvant treatment does not appear to provide much benefit in resectable patients but in the small subgroup of patients with borderline resectable/unresectable locally advanced disease it may increase the possibility of an R0 resection and, consequently, a substantial increase in survival duration. Use of capecitabine-based radiotherapy in patients with unresectable locally advanced disease appears to be more efficacious and better tolerated than gemcitabine-based chemoradiotherapy, with respect to survival outcomes. However, as with adjuvant treatment, the benefit of adding radiotherapy has not yet been definitively demonstrated. In patients with metastatic pancreatic cancer, targeting the stroma with nab-paclitaxel has shown promising results in a phase III trial setting when administered in combination with gemcitabine and, furthermore, this regimen is suitable for a broad range of patients due to its generally good tolerability profile. Because of its high toxicity, FOLFIRINOX is more suitable for younger patients with an excellent performance status who can withstand aggressive treatment and in patients with a worse performance status, gemcitabine monotherapy is considered to be a more appropriate treatment. Alternatively, gemcitabine in combination with erlotinib, the only targeted compound that has resulted in significant albeit small improvements in survival in patients with advanced disease, could be selected. However, the benefit-risk profile of this regimen is only favorable in a strictly defined, small patient subgroup who develop a treatment-related rash. Finally, with the elucidation of prognostic and predictive markers, treatment is expected to become ever more individualized, leading to improved efficacy outcomes and less unnecessary toxicity.

show abstract

Evidenz der Chemotherapie beim fortgeschrittenen Pankreaskarzinom

Heinemann

2013

Erkrankungen Des Pankreas

View full text Add to dashboard Cite

A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine.

Cited by 5 publications

References 0 publications

Molecular Targeted Approaches for Treatment of Pancreatic Cancer

Molecular Targeted Approaches for Treatment of Pancreatic Cancer

Recent Developments and Current Issues in the Treatment of Pancreatic Cancer

Evidenz der Chemotherapie beim fortgeschrittenen Pankreaskarzinom

Contact Info

Product

Resources

About